US President Donald Trump announced new agreements with nine pharmaceutical manufacturers, including Alcon and Astellas Pharma, expanding the "Most Favored Nation" (MFN) pricing mechanism to 26 manufacturers, covering 89% of the branded drug market. This initiative aims to lower US prescription drug prices to the lowest levels consistent with other developed nations. These manufacturers have pledged to invest at least $19.6 billion in US manufacturing and donate critical drug ingredients to the Strategic Active Pharmaceutical Ingredient Reserve (SAPIR) to reduce foreign dependence. The White House anticipates these MFN agreements will save Americans $600 billion over the next decade.